Brinker Int’l stock price target lowered to $144 by UBS ahead of earnings

Investing.comMonday, October 27, 2025 at 2:37:56 PM
Brinker Int’l stock price target lowered to $144 by UBS ahead of earnings
UBS has lowered its stock price target for Brinker International to $144 just ahead of the company's earnings report. This adjustment reflects concerns about the company's performance and market conditions, which could impact investor confidence. As earnings season approaches, such revisions can significantly influence stock prices and investor strategies.
— Curated by the World Pulse Now AI Editorial System

Was this article worth reading? Share it

Recommended Readings
Bloom Energy stock gains as UBS reiterates Buy rating on data center potential
PositiveFinancial Markets
Bloom Energy's stock is on the rise after UBS reaffirmed its Buy rating, highlighting the company's potential in the data center market. This endorsement from a major financial institution signals confidence in Bloom Energy's growth prospects, particularly as demand for sustainable energy solutions continues to increase. Investors are likely to view this as a positive indicator for the company's future performance.
UBS raises Commercial Metals stock price target to $66 on Foley acquisition
PositiveFinancial Markets
UBS has raised its price target for Commercial Metals to $66 following the company's acquisition of Foley. This move reflects confidence in Commercial Metals' growth potential and strategic direction, which could lead to increased investor interest and a stronger market position.
UBS files application for US banking licence
PositiveFinancial Markets
UBS has taken a significant step by filing an application for a US banking license, which could enhance its operations and presence in the American market. This move is important as it reflects UBS's commitment to expanding its services and adapting to the evolving financial landscape, potentially benefiting both the bank and its clients.
Mobileye stock holds steady as UBS reiterates Neutral rating on new award
NeutralFinancial Markets
Mobileye's stock remains stable as UBS maintains a Neutral rating following the company's recent award. This consistency in stock performance indicates investor confidence, despite the lack of a strong buy or sell signal from UBS. The award highlights Mobileye's ongoing innovation in the autonomous driving sector, which is crucial for its future growth and market position.
Lennox International stock price target lowered to $560 by UBS on weak demand
NegativeFinancial Markets
UBS has lowered its stock price target for Lennox International to $560, citing weak demand as a significant concern. This adjustment reflects broader market trends and could impact investor confidence in the company. Understanding these shifts is crucial for stakeholders as they navigate potential risks and opportunities in the HVAC industry.
Procter & Gamble stock rises as UBS reiterates Buy rating on earnings beat
PositiveFinancial Markets
Procter & Gamble's stock has seen a notable rise following UBS's decision to reiterate a Buy rating after the company reported better-than-expected earnings. This positive outlook from a major financial institution highlights investor confidence in Procter & Gamble's performance and growth potential, making it a significant development for shareholders and market watchers alike.
BCB Bancorp earnings beat, revenue topped estimates
PositiveFinancial Markets
BCB Bancorp has reported earnings that exceeded expectations, with revenue also surpassing estimates. This positive financial performance highlights the company's strong position in the market and suggests robust growth potential. Investors and stakeholders will likely view this as a sign of confidence in BCB Bancorp's future prospects.
Tech Has a Valuation Problem, Not an AI Bubble, RBC’s Calvasina Says
NegativeFinancial Markets
Lori Calvasina, head of US equity strategy at RBC Capital Markets, has expressed concerns about the tech sector's peak valuations and earnings revisions. She believes that these factors could indicate a troubling trend for investors. This matters because it highlights the potential risks in the tech market, which has been a significant driver of economic growth and investment. Understanding these dynamics is crucial for making informed financial decisions.
Latest from Financial Markets
Home Office squandered billions on asylum hotels, MPs say
NegativeFinancial Markets
A recent report by MPs reveals that the Home Office has wasted billions on asylum hotels due to flawed contracts and incompetent delivery. This mismanagement has left the department struggling to meet the growing demand for asylum accommodation, raising concerns about the effectiveness of government spending and the treatment of asylum seekers in the UK.
Argentine bonds and currency surge after victory for Javier Milei’s party
PositiveFinancial Markets
Argentina's financial markets are experiencing a significant boost following the electoral victory of Javier Milei's party. Investors are optimistic that this endorsement will ensure the continuation of the president's market-friendly reforms, which are crucial for the country's economic stability and growth. This surge in bonds and currency reflects a renewed confidence in Argentina's economic direction, making it a pivotal moment for both local and international investors.
Caroline Flack’s Mother Reveals Heartbreaking Regret in Disney+ Documentary
NegativeFinancial Markets
In a poignant new Disney+ documentary, Caroline Flack's mother opens up about her deep regrets following her daughter's tragic death. This heartfelt revelation sheds light on the struggles faced by those dealing with mental health issues and the importance of support systems. It matters because it encourages conversations around mental health and the impact of loss, reminding us to cherish our loved ones and seek help when needed.
Keurig Dr Pepper Soars; Carter's Falls; Avidity Biosciences Rallies
PositiveFinancial Markets
Keurig Dr Pepper's shares have surged ahead of the New York market opening after the company raised its fiscal 2025 sales growth forecast to a high-single-digit range, a significant upgrade from its previous outlook. This positive shift comes alongside a $7 billion financing deal with Apollo and KKR to support its acquisition of JDE Peet’s NV, addressing investor concerns about debt levels. Meanwhile, Carter's shares have declined, and Avidity Biosciences has seen a rally, highlighting the dynamic nature of the stock market.
Shaw Thomas, president and CEO of Retractable, buys $338 in RVP
PositiveFinancial Markets
Shaw Thomas, the president and CEO of Retractable, has made a notable investment by purchasing $338 in RVP. This move highlights his confidence in the company's future and could signal positive growth ahead. Such investments from leadership often inspire trust among stakeholders and can lead to increased interest in the company's performance.
Revolution Medicines stock rises after FDA grants Orphan Drug Designation
PositiveFinancial Markets
Revolution Medicines saw a significant boost in its stock price following the FDA's decision to grant Orphan Drug Designation for its promising treatment. This designation is crucial as it provides incentives for the development of drugs aimed at rare diseases, potentially leading to faster market access and increased funding opportunities. Investors are optimistic about the company's future prospects, as this recognition could pave the way for successful clinical trials and ultimately benefit patients in need.